Skip to main content

Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that management will participate in webcast fireside chats at the following investor conferences:

Citi’s 2025 Global Healthcare Conference
Date/Time: Tuesday, December 2, 2025 at 2:30 p.m. ET

Evercore 8th Annual Healthcare Conference 
Date/Time: Wednesday, December 3, 2025 at 2:10 p.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 30 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company leading the way in complement science to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two C3-targeting medicines approved to treat four serious diseases. Breakthroughs for patients include the first-ever therapy for geographic atrophy, a leading cause of blindness, and the first treatment for patients 12 and older with C3G or primary IC-MPGN, two severe, rare kidney diseases. We believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on LinkedIn and X.

Investor Contact: 
Eva Stroynowski
ir@apellis.com
617.938.6229


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.72
+4.57 (2.27%)
AAPL  265.45
+1.57 (0.60%)
AMD  200.29
-2.79 (-1.37%)
BAC  53.40
+0.66 (1.24%)
GOOG  303.16
+0.34 (0.11%)
META  638.27
-1.02 (-0.16%)
MSFT  399.96
+3.10 (0.78%)
NVDA  189.92
+4.95 (2.68%)
ORCL  155.78
+1.81 (1.18%)
TSLA  413.36
+2.73 (0.66%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.